Technology Insight: utility of TNF-α-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Nature Clinical Practice Oncology

• Publication date

  2006-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/ncponc0426
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Preoperative chemoradiation treatment strategies for localized sarcoma

  2007cited by this paper
• Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor‐α and melphalan for limb‐threatening soft tissue sarcoma

  2006cited by this paper
• The palliative value of tumor necrosis factor α‐based isolated limb perfusion in patients with metastatic sarcoma and melanoma

  2006cited by this paper
• Isolated Limb Perfusions With Tumor Necrosis Factor and Melphalan for Locally Recurrent Soft Tissue Sarcoma in Previously Irradiated Limbs

  2005cited by this paper
• Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-α be better?

  2005cited by this paper
• TNF-based isolated limb perfusion in unresectable extremity desmoid tumours.

  2005cited by this paper
• TNF dose reduction in isolated limb perfusion.

  2005cited by this paper
• Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.

  2005cited by this paper
• Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas.

  2005cited by this paper
• Efficacy of Repeat Isolated Limb Perfusions With Tumor Necrosis Factor α and Melphalan for Multiple In-Transit Metastases in Patients with Prior Isolated Limb Perfusion Failure

  2005cited by this paper
• Hyperthermic Isolated Perfusion With Low-Dose Tumor Necrosis Factor α and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcomas

  2005cited by this paper
• Isolated Limb Perfusion With Tumor Necrosis Factor and Melphalan Prevents Amputation in Patients With Multiple Sarcomas in Arm or Leg

  2004influential reference
• Tumor necrosis factor‐α augmented tumor response in B16BL6 melanoma‐bearing mice treated with stealth liposomal doxorubicin (Doxil®) correlates with altered Doxil® pharmacokinetics

  2004cited by this paper
• A prospective evaluation of isolated limb perfusion with doxorubicin in patients with unresectable extremity sarcomas

  2004cited by this paper
• Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

  2004cited by this paper
• Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.

  2004cited by this paper
• Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-α and Melphalan for Bulky In-Transit Melanoma Metastases

  2004cited by this paper
• One Hundred Consecutive Isolated Limb Perfusions With TNF-α and Melphalan in Melanoma Patients With Multiple In-Transit Metastases

  2004cited by this paper
• Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-α-based isolated hepatic perfusion

  2003cited by this paper
• Isolated limb perfusion with tumor necrosis factor‐α and melphalan for patients with unresectable soft tissue sarcoma of the extremities

  2003cited by this paper
• Fifty Tumor Necrosis Factor–Based Isolated Limb Perfusions for Limb Salvage in Patients Older Than 75 Years With Limb-Threatening Soft Tissue Sarcomas and Other Extremity Tumors

  2003cited by this paper
• Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable Stewart-Treves lymphangiosarcoma

  2002cited by this paper
• Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity

  2002cited by this paper
• Hepatitis B and C virus prevalence in a rural area of South Korea: the role of acupuncture

  2002cited by this paper
• Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas

  2002cited by this paper
• Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial.

  2002cited by this paper
• Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.

  2001cited by this paper
• Functional outcome after preoperative isolated limb perfusion with rhTNFalpha/Melphalan for high-grade extremity sarcoma

  2001cited by this paper
• TNF is here to stay--revisited.

  2001cited by this paper
• Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas.

  2001cited by this paper
• Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion

  2000cited by this paper
• TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects

  2000cited by this paper
• Systemic Toxicity and Cytokine/Acute Phase Protein Levels in Patients After Isolated Limb Perfusion With Tumor Necrosis Factor-a Complicated by High Leakage

  2000cited by this paper
• Low‐dose tumor necrosis factor‐α augments antitumor activity of stealth liposomal doxorubicin (DOXIL®) in soft tissue sarcoma‐bearing rats

  2000cited by this paper
• Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.

  2000cited by this paper
• Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.

  1999cited by this paper
• Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats

  1999cited by this paper
• Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan.

  1999cited by this paper
• Isolated limb perfusion with high-dose tumor necrosis factor alpha and melphalan for Kaposi sarcoma.

  1999cited by this paper
• Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study.

  1999cited by this paper
• Limb desmoid tumors: a possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan.

  1999cited by this paper
• Absence of Severe Systemic Toxicity After Leakage-Controlled Isolated Limb Perfusion With Tumor Necrosis Factor-α and Melphalan

  1999cited by this paper
• Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity.

  1999cited by this paper
• Isolated Limb Perfusion With High-Dose Tumor Necrosis Factor α and Melphalan for Kaposi Sarcoma

  1999cited by this paper
• Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern.

  1998cited by this paper
• Hyperthermic isolated limb perfusion with tumour necrosis factor α and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?

  1998cited by this paper
• Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma.

  1998cited by this paper
• Evidence for the involvement of endotheliai cell integrin αVβ3 in the disruption of the tumor vascuiature induced by TNF and IFN-γ

  1998cited by this paper
• High dose tumor necrosis factor‐α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation

  1997cited by this paper
• Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.

  1997influential reference
• Treatment of melanoma in-transit metastases confined to the limb

  1996cited by this paper
• Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.

  1996cited by this paper
• Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.

  1996cited by this paper
• Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts.

  1996cited by this paper
• Treatment of Recurrent Sarcoma of the Extremities by Isolated Limb Perfusion Using Tumor Necrosis Factor Alpha and Melphalan

  1996cited by this paper
• Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.

  1996cited by this paper
• 31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF‐α+ melphalan isolated limb perfusion

  1995cited by this paper
• Rationale for using TNFα and chemotherapy in regional therapy of melanoma

  1994cited by this paper
• Isolated limb perfusion.

  1994cited by this paper
• Harly endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high‐dose tumour necrosis factor alpha (rTNFα)

  1994cited by this paper
• Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha).

  1994cited by this paper
• Phase II study on neoadjuvant hyperthermic‐antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas

  1994cited by this paper
• Low‐dose tumour necrosis factor α and melphalan in hyperthermic isolated limb perfusion

  1993cited by this paper
• Treatment of Irresectable Soft Tissue Sarcomas of the Limbs by Isolation Perfusion with High Dose TNFα in Combination with Interferon-γ and Melphalan

  1993cited by this paper
• Regional therapy of melanoma.

  1993cited by this paper
• Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs

  1992cited by this paper
• High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.

  1992cited by this paper
• Comparison of Amputation With Limb‐sparing Operations for Adult Soft Tissue Sarcoma of the Extremity

  1992cited by this paper
• Is local recurrence of minor importance for metastases in soft tissue sarcoma?

  1991cited by this paper
• The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival

  1990cited by this paper
• Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities

  1989cited by this paper
• Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities.

  1988cited by this paper
• Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics.

  1988cited by this paper
• The treatment of soft tissue sarcomas of the extremities: Prospective randomized evaluations of(1)limb sparing surgery plus radiation therapy compared with amputation, and(2)the role of adjuvant chemotherapy

  1983cited by this paper
• Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions.

  1982cited by this paper
• The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy.

  1982cited by this paper
• Chemotherapy of sarcomas of the limbs by regional perfusion.

  1977cited by this paper
• Chemotherapy of Cancer: Regional Perfusion Utilizing an Extracorporeal Circuit

  1958cited by this paper

• Immunocytokines and cytokine neutralization for cancer immunotherapy.

  2025cites this paper
• Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy

  2025cites this paper
• Isolated Limb Perfusion for Extremity Soft Tissue Sarcoma and Malignant Melanoma

  2024cites this paper
• PHARMACEUTICAL AND CLINICAL CHALLENGES OF BIOLOGICAL MEDICINES: ONGOING HURDLES FROM DRUG DEVELOPMENT TO THERAPEUTIC APPLICATIONS

  2024cites this paper
• Combining high throughput array synthesis and growth algorithm to discover TNF-α binders with new structures and properties.

  2023cites this paper
• Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization

  2022cites this paper
• Liposomal Drug Delivery Systems for Cancer Therapy: The Rotterdam Experience

  2022cites this paper
• Tumor Necrosis Factor: What Is in a Name?

  2022cites this paper
• Human Tumor Targeted Cytotoxic Mast Cells for Cancer Immunotherapy

  2022cites this paper
• Biomedical Applications of a Novel Class of High-Affinity Peptides.

  2021cites this paper
• Oncological outcome after hyperthermic isolated limb perfusion for primarily unresectable versus locally recurrent soft tissue sarcoma of extremities.

  2020cites this paper
• Immunocytokines are a promising immunotherapeutic approach against glioblastoma

  2020cites this paper
• Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine

  2020cites this paper
• Isolated limb perfusion in sarcoma: experience with melphalan as single chemotherapeutic agent at the National Cancer Institute of Colombia

  2019cites this paper
• Trial Data for Sarcoma

  2019cites this paper
• Ripoptocide – A Spark for Inflammation

  2019cites this paper
• THE PREVENTION OF OBESITY-ASSOCIATED COLORECTAL CANCER VIA DIETARY SUPPRESSION OF INFLAMMATION-DRIVEN WNT-SIGNALING

  2019cites this paper
• Tumor Vasculature Targeted TNFα Therapy: Reversion of Microenvironment Anergy and Enhancement of the Anti-tumor Efficiency.

  2018cites this paper
• Differentiation of functional human mast cells from adipose derived stem cells and their application in allergo-oncology and the treatment of breast cancer

  2018influential citation
• Therapie von Hochrisiko-Weichteilsarkomen bei Erwachsenen

  2018cites this paper
• Should we target TNF receptors in the intestinal epithelium with glucocorticoids during systemic inflammation?

  2018cites this paper
• Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy

  2018cites this paper
• Oxaliplatin and Infliximab Combination Synergizes in Inducing Colon Cancer Regression

  2017cites this paper
• Hyperthermic isolated limb perfusion. The switch from Steinmann pins to Omni-tract assisted isolation.

  2017cites this paper
• Cancer nanomedicines: Opportunities and challenges

  2017influential citation
• Perfusión aislada de extremidades en sarcomas: experiencia con melfalán como agente único quimioterapéutico en el Instituto Nacional de Cancerología (INC) de Colombia

  2017cites this paper
• Chapter 5 – Therapy of Melanoma

  2017cites this paper
• Dendritic Mesoporous Silica Nanoparticles for pH‐Stimuli‐Responsive Drug Delivery of TNF‐Alpha

  2017cites this paper
• Isolated limb perfusion for the management limb threatening soft tissue sarcomas: The role of histological type on clinical outcomes.

  2017cites this paper
• Targeted Cancer Therapy Using Fusion Protein of TNFα and Tumor-Associated Fibronectin-Specific Aptide.

  2017cites this paper
• Trial Watch—Immunostimulation with cytokines in cancer therapy

  2016cites this paper
• Integrating new imaging modalities in breast cancer management

  2016cites this paper
• Looking for answers: the current status of neoadjuvant treatment in localized soft tissue sarcomas

  2016cites this paper
• IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα

  2016cites this paper
• Chapter 7 Surgical Experiences with Intraoperative Gamma Cameras

  2016cites this paper
• Targeting antitumor effect of rhTNF-α fusion protein mediated by matrix metalloproteinase-2.

  2015cites this paper
• Trial watch

  2014cites this paper
• Successful engineering cancer immunotherapy

  2014cites this paper
• Recent advances in osteosarcoma.

  2014cites this paper
• Isolated regional perfusion for metastases of malignant melanoma - Clinical and experimental studies

  2013cites this paper
• Changes in Hepatic Blood Flow During Transcatheter Arterial Infusion with Heated Saline in Hepatic VX2 Tumor

  2013cites this paper
• Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium.

  2013cites this paper
• Tumour necrosis factor and cancer

  2013cites this paper
• Affinity Purification of Tumor Necrosis Factor-α Expressed in Raji Cells by Produced scFv Antibody Coupled CNBr-Activated Sepharose.

  2013cites this paper
• The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-α: a comparison with the whole group of resected soft tissue sarcomas

  2013cites this paper
• Routes of Delivery for Biological Drug Products

  2013cites this paper
• Biologic response modifiers

  2013cites this paper
• Human Cancer Resistance to Trail-Apoptotic Pathway-Targeted Therapies

  2013cites this paper
• Current Status and Advance of Chemotherapy for Soft Tissue Sarcoma

  2013influential citation
• Weichteilsarkome

  2012cites this paper
• Size-Based Clinical Response Evaluation is Insufficient to Assess Clinical Response of Sarcomas Treated with Isolated Limb Perfusion with TNF-α and Melphalan

  2012cites this paper
• 软组织肉瘤化疗现状及其进展 Current Status and Advance of Chemotherapy for Soft Tissue Sarcoma

  2012cites this paper
• Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: Systematic review of clinical efficacy and quality assessment of reported trials

  2012cites this paper
• Trial Watch

  2012cites this paper
• Tratamiento regional del sarcoma y melanoma localmente avanzado de la extremidad mediante la perfusión aislada con tumor necrosis factor α y melfalan asociada a hipertermia

  2012cites this paper
• Aktueller Stand der neoadjuvanten Therapie bei Weichteilsarkomen

  2011cites this paper
• Antibody-Based Targeting of Tumor Vasculature and Stroma

  2011cites this paper
• Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF‐α and melphalan

  2011cites this paper
• Increased shedding of soluble TNF-receptor 1 during hyperthermic TNF-α-based isolated limb perfusion

  2011cites this paper
• Signal integration, crosstalk mechanisms and networks in the function of inflammatory cytokines.

  2011cites this paper
• Overexpression of the drug resistance‐associated protein metallothionein does not correlate with response of sarcomas to isolated limb perfusion treatment

  2010cites this paper
• Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study.

  2010cites this paper
• glioblastomas: opportunities for targeted therapeutics

  2010cites this paper
• Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics

  2010cites this paper
• Cutaneous melanoma in the elderly: epidemiology, prognosis and treatment

  2010cites this paper
• Apoptosis assays for quantifying the bioactivity of anticancer drug products.

  2010cites this paper
• Tumor vasculature as target for therapeutic intervention

  2010cites this paper
• Monitoring system for isolated limb perfusion based on a portable gamma camera

  2009cites this paper
• RNAi‐mediated silencing of insulin receptor substrate‐4 enhances actinomycin D‐ and tumor necrosis factor‐α‐induced cell death in hepatocarcinoma cancer cell lines

  2009cites this paper
• Heat-responsive gene expression for gene therapy.

  2009cites this paper
• Adjuvant chemotherapy in localized soft tissue sarcomas: still not proven.

  2009cites this paper
• Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case.

  2009cites this paper
• Targeting of TRAIL Apoptotic Pathways for Glioblastoma Therapies

  2009cites this paper
• Isolated Limb Infusion

  2009cites this paper
• TNF and manipulation of the tumor cell-stromal interface: "ways to make chemotherapy effective".

  2008influential citation
• Tumor necrosis factor‐mediated interactions between inflammatory response and tumor vascular bed

  2008cites this paper
• Tumor necrosis factor and cancer, buddies or foes?

  2008cites this paper
• To kill a tumor cell: the potential of proapoptotic receptor agonists.

  2008cites this paper
• Effectiveness of regional chemotherapy with TNF-α/Melphalan in advanced soft tissue sarcoma of the extremities

  2008cites this paper
• Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha

  2008cites this paper
• Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein

  2008cites this paper
• Selective anticancer strategies via intervention of the death pathways relevant to cell transformation

  2008cites this paper
• Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.

  2007cites this paper
• Purification and characterization of RGD tumor-homing peptide conjugated human tumor necrosis factor α over-expressed in Escherichia coli

  2007cites this paper
• Isolated Limb Perfusion with Tumor Necrosis Factor-Alpha and Melphalan

  2007cites this paper
• Oncoimmunology: Some fundamental problems of cancer immunotherapy

  2007cites this paper
• Antibody-based targeting of the tumor vasculature.

  2007cites this paper
• Isolated Limb Perfusion with Tumor Necrosis Factor-Alpha and Melphalan An Alternative to Amputation for Locally Advanced Soft Tissue Sarcomas

  2007cites this paper
• Molecular, colloidal and cellular approaches to attack tumor vasculature

  2007cites this paper
• Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.

  2007cites this paper
• Clinical Utility of TNF-based Isolated Limb Perfusion to achieve Limb Salvage

  2006cites this paper
• Early destruction of tumor vasculature in tumor necrosis factor-&agr;-based isolated limb perfusion is responsible for tumor response

  2006cites this paper
• Efficiency of recombinant human TNF in human cancer therapy.

  2006cites this paper